Biontech and dualitybio initiate pivotal phase 3 trial of antibody-drug conjugate candidate bnt323/db-1303 in metastatic breast cancer

Mainz, germany and shanghai, china, january 22, 2024 – biontech se (nasdaq: bntx, “biontech”) and duality biologics (suzhou) co., ltd. (“dualitybio”) today announced that the first patient with metastatic breast cancer has been treated in a pivotal phase 3 trial evaluating the efficacy and safety of the next-generation antibody-drug conjugate (“adc”) candidate bnt323/db-1303 targeting the human epidermal growth factor receptor 2 (“her2”), a cancer cell surface protein.
BNTX Ratings Summary
BNTX Quant Ranking